Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1969 1
1970 1
1973 1
1980 1
1982 2
1984 3
1986 2
1987 1
1988 1
1993 1
1994 1
1995 1
1996 3
1997 10
1998 10
1999 13
2000 29
2001 34
2002 50
2003 59
2004 82
2005 95
2006 114
2007 99
2008 141
2009 144
2010 211
2011 268
2012 325
2013 392
2014 483
2015 547
2016 525
2017 576
2018 578
2019 597
2020 622
2021 257
Text availability
Article attribute
Article type
Publication date

Search Results

5,587 results
Results by year
Filters applied: . Clear all
Page 1
Metformin - its potential anti-cancer and anti-aging effects.
Podhorecka M, Ibanez B, Dmoszyńska A. Podhorecka M, et al. Postepy Hig Med Dosw (Online). 2017 Mar 2;71(0):170-175. doi: 10.5604/01.3001.0010.3801. Postepy Hig Med Dosw (Online). 2017. PMID: 28258677 Free article. Review.
The generally accepted mechanism of metformin's effect is stimulation of adenosine monophosphate (AMP)-activated protein kinase (AMPK). ...The aim of this review is to describe the potential anti-cancer and anti-aging properties of metformin and discus …
The generally accepted mechanism of metformin's effect is stimulation of adenosine monophosphate (AMP)-activated protein kinas …
Metformin in cancer treatment and prevention.
Morales DR, Morris AD. Morales DR, et al. Annu Rev Med. 2015;66:17-29. doi: 10.1146/annurev-med-062613-093128. Epub 2014 Nov 6. Annu Rev Med. 2015. PMID: 25386929 Review.
Basic science has provided a better understanding of the mechanism of action of metformin and the potential for metformin to modulate molecular pathways involved in cancer cell signaling and metabolism. This article outlines the link between metformin
Basic science has provided a better understanding of the mechanism of action of metformin and the potential for metformin to m …
Metformin in colorectal cancer: molecular mechanism, preclinical and clinical aspects.
Kamarudin MNA, Sarker MMR, Zhou JR, Parhar I. Kamarudin MNA, et al. J Exp Clin Cancer Res. 2019 Dec 12;38(1):491. doi: 10.1186/s13046-019-1495-2. J Exp Clin Cancer Res. 2019. PMID: 31831021 Free PMC article. Review.
This review aims to provide the comprehensive information on the use of metformin at preclinical and clinical stages among colorectal cancer patients. We highlight the efficacy of metformin as an anti-proliferative, chemopreventive, apoptosis inducing agent, …
This review aims to provide the comprehensive information on the use of metformin at preclinical and clinical stages among colorectal …
Repurposing metformin for the prevention of cancer and cancer recurrence.
Heckman-Stoddard BM, DeCensi A, Sahasrabuddhe VV, Ford LG. Heckman-Stoddard BM, et al. Diabetologia. 2017 Sep;60(9):1639-1647. doi: 10.1007/s00125-017-4372-6. Epub 2017 Aug 3. Diabetologia. 2017. PMID: 28776080 Free PMC article. Review.
Multiple epidemiological studies have documented an association between metformin, used for treatment of type 2 diabetes, and reduced cancer incidence and mortality. ...Thus, enthusiasm remains for understanding the role of metformin in cancer through …
Multiple epidemiological studies have documented an association between metformin, used for treatment of type 2 diabetes, and reduced …
Metformin as an adjuvant treatment for cancer: a systematic review and meta-analysis.
Coyle C, Cafferty FH, Vale C, Langley RE. Coyle C, et al. Ann Oncol. 2016 Dec;27(12):2184-2195. doi: 10.1093/annonc/mdw410. Epub 2016 Sep 28. Ann Oncol. 2016. PMID: 27681864 Free PMC article. Review.
BACKGROUND: Metformin use has been associated with a reduced risk of developing cancer and an improvement in overall cancer survival rates in meta-analyses, but, to date, evidence to support the use of metformin as an adjuvant therapy in individual …
BACKGROUND: Metformin use has been associated with a reduced risk of developing cancer and an improvement in overall cancer
Metformin and pancreatic cancer: Is there a role?
De Souza A, Khawaja KI, Masud F, Saif MW. De Souza A, et al. Cancer Chemother Pharmacol. 2016 Feb;77(2):235-42. doi: 10.1007/s00280-015-2948-8. Epub 2016 Jan 6. Cancer Chemother Pharmacol. 2016. PMID: 26740120 Review.
Anti-hyperglycemic treatments for type 2 diabetes mellitus that induce hyperinsulinemia (i.e., sulfonylureas) are thought to increase cancer risk, whereas treatments that lower insulin resistance and hyperinsulinemia (i.e., metformin) are considered cancer pr …
Anti-hyperglycemic treatments for type 2 diabetes mellitus that induce hyperinsulinemia (i.e., sulfonylureas) are thought to increase can
Metformin and Prostate Cancer: a New Role for an Old Drug.
Whitburn J, Edwards CM, Sooriakumaran P. Whitburn J, et al. Curr Urol Rep. 2017 Jun;18(6):46. doi: 10.1007/s11934-017-0693-8. Curr Urol Rep. 2017. PMID: 28444639 Free PMC article. Review.
PURPOSE OF REVIEW: Since epidemiological studies first demonstrated a potential positive effect of metformin in reducing cancer incidence and mortality, there has been an increased interest in not only better understanding metformin's mechanisms of act …
PURPOSE OF REVIEW: Since epidemiological studies first demonstrated a potential positive effect of metformin in reducing cancer
Metformin in cancer.
Mallik R, Chowdhury TA. Mallik R, et al. Diabetes Res Clin Pract. 2018 Sep;143:409-419. doi: 10.1016/j.diabres.2018.05.023. Epub 2018 May 26. Diabetes Res Clin Pract. 2018. PMID: 29807101 Review.
Non-AMPK dependent protective pathways may include reduction of insulin, insulin-like growth factor-1, leptin, inflammatory pathways and potentiation of adiponectin, all of which may have a role in tumourigenesis. A role in inhibiting cancer stem cells is also postulated. …
Non-AMPK dependent protective pathways may include reduction of insulin, insulin-like growth factor-1, leptin, inflammatory pathways and pot …
Metformin, the aspirin of the 21st century: its role in gestational diabetes mellitus, prevention of preeclampsia and cancer, and the promotion of longevity.
Romero R, Erez O, Hüttemann M, Maymon E, Panaitescu B, Conde-Agudelo A, Pacora P, Yoon BH, Grossman LI. Romero R, et al. Am J Obstet Gynecol. 2017 Sep;217(3):282-302. doi: 10.1016/j.ajog.2017.06.003. Epub 2017 Jun 12. Am J Obstet Gynecol. 2017. PMID: 28619690 Free PMC article. Review.
There is considerable evidence to suggest that this agent is safe during pregnancy. New literature on the role of metformin as a chemotherapeutic adjuvant in the prevention of cancer and in prolonging life and protecting against aging is reviewed briefly. Herein, we …
There is considerable evidence to suggest that this agent is safe during pregnancy. New literature on the role of metformin as a chem …
Metformin as an anti-cancer agent: actions and mechanisms targeting cancer stem cells.
Saini N, Yang X. Saini N, et al. Acta Biochim Biophys Sin (Shanghai). 2018 Feb 1;50(2):133-143. doi: 10.1093/abbs/gmx106. Acta Biochim Biophys Sin (Shanghai). 2018. PMID: 29342230 Review.
Metformin, a first line medication for type II diabetes, initially entered the spotlight as a promising anti-cancer agent due to epidemiologic reports that found reduced cancer risk and improved clinical outcomes in diabetic patients taking metformin.
Metformin, a first line medication for type II diabetes, initially entered the spotlight as a promising anti-cancer agent due
5,587 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page